{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:35Z","timestamp":1792047815645,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R16GM149412"],"award-info":[{"award-number":["R16GM149412"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["U54MD007595"],"award-info":[{"award-number":["U54MD007595"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K99HL161423"],"award-info":[{"award-number":["K99HL161423"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03054-2","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T22:01:58Z","timestamp":1730498518000},"page":"1308-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors"],"prefix":"10.1007","volume":"57","author":[{"given":"Anthony","family":"Dumas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusoodanan","family":"Mottamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Afosah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-2662","authenticated-orcid":false,"given":"Rami A.","family":"Al-Horani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"3054_CR1","doi-asserted-by":"crossref","unstructured":"Weidmann H, Heikaus L, Long AT, Naudin C, Schl\u00fcter H, Renn\u00e9 T The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity (2017). Biochim Biophys Acta Mol Cell Res 1864(11 Pt B):2118\u20132127","DOI":"10.1016\/j.bbamcr.2017.07.009"},{"issue":"22","key":"3054_CR2","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","volume":"120","author":"T Renn\u00e9","year":"2012","unstructured":"Renn\u00e9 T, Schmaier AH, Nickel KF, Blomb\u00e4ck M, Maas C (2012) In vivo roles of factor XII. Blood 120(22):4296\u20134303","journal-title":"Blood"},{"key":"3054_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cellsig.2018.08.006","volume":"51","author":"M Didiasova","year":"2018","unstructured":"Didiasova M, Wujak L, Schaefer L, Wygrecka M (2018) Factor XII in coagulation, inflammation and beyond. Cell Signal 51:257\u2013265","journal-title":"Cell Signal"},{"key":"3054_CR4","doi-asserted-by":"publisher","first-page":"112753","DOI":"10.1016\/j.ejmech.2020.112753","volume":"208","author":"C Davoine","year":"2020","unstructured":"Davoine C, Bouckaert C, Fillet M, Pochet L (2020) Factor XII\/XIIa inhibitors: their discovery, development, and potential indications. Eur J Med Chem 208:112753","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3054_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/bloodadvances.2018016337","volume":"2","author":"A Dementiev","year":"2018","unstructured":"Dementiev A, Silva A, Yee C, Li Z, Flavin MT, Sham H, Partridge JR (2018) Structures of human plasma \u03b2-factor XIIa cocrystallized with potent inhibitors. Blood Adv 2(5):549\u2013558","journal-title":"Blood Adv"},{"issue":"4","key":"3054_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/rth2.12235","volume":"3","author":"AH Schmaier","year":"2019","unstructured":"Schmaier AH, Stavrou EX (2019) Factor XII - what\u2019s important but not commonly thought about. Res Pract Thromb Haemost 3(4):599\u2013606","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"3054_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1084\/jem.20052458","volume":"203","author":"C Kleinschnitz","year":"2006","unstructured":"Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renn\u00e9 C, Gailani D, Nieswandt B, Renn\u00e9 T (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203(3):513\u2013518","journal-title":"J Exp Med"},{"issue":"2","key":"3054_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1084\/jem.20050664","volume":"202","author":"T Renn\u00e9","year":"2005","unstructured":"Renn\u00e9 T, Pozgajov\u00e1 M, Gr\u00fcner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202(2):271\u2013281","journal-title":"J Exp Med"},{"issue":"2","key":"3054_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bcmd.2005.12.014","volume":"36","author":"T Renn\u00e9","year":"2006","unstructured":"Renn\u00e9 T, Nieswandt B, Gailani D (2006) The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis 36(2):148\u2013151","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"3054_CR10","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/ATVBAHA.114.303315","volume":"34","author":"MJ Kuijpers","year":"2014","unstructured":"Kuijpers MJ, van der Meijden PE, Feijge MA, Mattheij NJ, May F, Govers-Riemslag J, Meijers JC, Heemskerk JW, Renn\u00e9 T, Cosemans JM (2014) Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 34(8):1674\u20131680","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3054_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3389\/fimmu.2019.02011","volume":"10","author":"T Renn\u00e9","year":"2019","unstructured":"Renn\u00e9 T, Stavrou EX (2019) Roles of factor XII in Innate Immunity. Front Immunol 10:2011","journal-title":"Front Immunol"},{"issue":"17","key":"3054_CR12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-569111","volume":"131","author":"C Maas","year":"2018","unstructured":"Maas C, Renn\u00e9 T (2018) Coagulation factor XII in thrombosis and inflammation. Blood 131(17):1903\u20131909","journal-title":"Blood"},{"issue":"4","key":"3054_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1160\/TH13-08-0668","volume":"111","author":"Y Xu","year":"2014","unstructured":"Xu Y, Cai TQ, Castriota G, Zhou Y, Hoos L, Jochnowitz N, Loewrigkeit C, Cook JA, Wickham A, Metzger JM, Ogletree ML, Seiffert DA, Chen Z (2014) Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 111(4):694\u2013704","journal-title":"Thromb Haemost"},{"issue":"3","key":"3054_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/jpet.116.238493","volume":"360","author":"CM Barbieri","year":"2017","unstructured":"Barbieri CM, Wang X, Wu W, Zhou X, Ogawa AM, O\u2019Neill K, Chu D, Castriota G, Seiffert DA, Gutstein DE, Chen Z (2017) Factor XIIa as a Novel Target for thrombosis: Target Engagement requirement and efficacy in a rabbit model of Microembolic signals. J Pharmacol Exp Ther 360(3):466\u2013475","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"3054_CR15","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","volume":"123","author":"JW Yau","year":"2014","unstructured":"Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenko AS, Monia BP, Weitz JI (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123(13):2102\u20132107","journal-title":"Blood"},{"issue":"222","key":"3054_CR16","doi-asserted-by":"publisher","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","volume":"6","author":"M Larsson","year":"2014","unstructured":"Larsson M, Rayzman V, Nolte MW, Nickel KF, Bj\u00f6rkqvist J, J\u00e4ms\u00e4 A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broom\u00e9 M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renn\u00e9 T (2014) A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 6(222):222ra17","journal-title":"Sci Transl Med"},{"issue":"11","key":"3054_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","volume":"123","author":"A Matafonov","year":"2014","unstructured":"Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renn\u00e9 T, Morrissey JH, Gruber A, Gailani D (2014) Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 123(11):1739\u20131746","journal-title":"Blood"},{"issue":"1","key":"3054_CR18","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1038\/s41467-020-17648-w","volume":"11","author":"J Wilbs","year":"2020","unstructured":"Wilbs J, Kong XD, Middendorp SJ, Prince R, Cooke A, Demarest CT, Abdelhafez MM, Roberts K, Umei N, Gonschorek P, Lamers C, Deyle K, Rieben R, Cook KE, Angelillo-Scherrer A, Heinis C (2020) Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. Nat Commun 11(1):3890","journal-title":"Nat Commun"},{"issue":"12","key":"3054_CR19","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/13543776.2021.1945580","volume":"31","author":"DV Kalinin","year":"2021","unstructured":"Kalinin DV (2021) Factor XII(a) inhibitors: a review of the patent literature. Expert Opin Ther Pat 31(12):1155\u20131176","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"3054_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12195-020-00657-6","volume":"14","author":"TCL Kohs","year":"2020","unstructured":"Kohs TCL, Lorentz CU, Johnson J, Puy C, Olson SR, Shatzel JJ, Gailani D, Hinds MT, Tucker EI, Gruber A, McCarty OJT, Wallisch M (2020) Development of coagulation factor XII antibodies for inhibiting vascular device-related thrombosis. Cell Mol Bioeng 14(2):161\u2013175","journal-title":"Cell Mol Bioeng"},{"issue":"6","key":"3054_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/joim.12430","volume":"278","author":"E Kenne","year":"2015","unstructured":"Kenne E, Nickel KF, Long AT, Fuchs TA, Stavrou EX, Stahl FR, Renn\u00e9 T (2015) Factor XII: a novel target for safe prevention of thrombosis and inflammation. J Intern Med 278(6):571\u2013585","journal-title":"J Intern Med"},{"key":"3054_CR22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-57011","author":"A Goel","year":"2023","unstructured":"Goel A, Tathireddy H, Wang SH, Vu HH, Puy C, Hinds MT, Zonies D, McCarty OJT, Shatzel JJ (2023) Targeting the contact pathway of Coagulation for the Prevention and Management of Medical device-Associated thrombosis. Semin Thromb Hemost. https:\/\/doi.org\/10.1055\/s-0043-57011","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"3054_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1517\/14728222.7.2.277","volume":"7","author":"J Howl","year":"2003","unstructured":"Howl J, Payne SJ (2003) Bradykinin receptors as a therapeutic target. Expert Opin Ther Targets 7(2):277\u2013285","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"3054_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","volume":"80","author":"HJ Longhurst","year":"2019","unstructured":"Longhurst HJ, Bork K (2019) Hereditary Angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond) 80(7):391\u2013398","journal-title":"Br J Hosp Med (Lond)"},{"key":"3054_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3389\/fimmu.2017.01115","volume":"8","author":"L Bender","year":"2017","unstructured":"Bender L, Weidmann H, Rose-John S, Renn\u00e9 T, Long AT (2017) Factor XII-Driven inflammatory reactions with implications for Anaphylaxis. Front Immunol 8:1115","journal-title":"Front Immunol"},{"key":"3054_CR26","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.1038\/ncomms11626","volume":"7","author":"K G\u00f6bel","year":"2016","unstructured":"G\u00f6bel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, Ruck T, Glumm S, Langhauser F, Kraft P, Krug TF, Breuer J, Herold M, Gross CC, Beckmann D, Korb-Pap A, Schuhmann MK, Kuerten S, Mitroulis I, Ruppert C, Nolte MW, Panousis C, Klotz L, Kehrel B, Korn T, Langer HF, Pap T, Nieswandt B, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG (2016) Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun 7:11626","journal-title":"Nat Commun"},{"issue":"18","key":"3054_CR27","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2016-11-753202","volume":"129","author":"ZL Chen","year":"2017","unstructured":"Chen ZL, Revenko AS, Singh P, MacLeod AR, Norris EH, Strickland S (2017) Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. Blood 129(18):2547\u20132556","journal-title":"Blood"},{"issue":"3","key":"3054_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/rth2.12217","volume":"3","author":"V Raghunathan","year":"2019","unstructured":"Raghunathan V, Zilberman-Rudenko J, Olson SR, Lupu F, McCarty OJT, Shatzel JJ (2019) The contact pathway and sepsis. Res Pract Thromb Haemost 3(3):331\u2013339. https:\/\/doi.org\/10.1002\/rth2.12217","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"3054_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/1871525721666221031141323","volume":"21","author":"RA Al-Horani","year":"2023","unstructured":"Al-Horani RA, Afosah DK, Mottamal M (2023) Triazol-1-yl Benzamides promote anticoagulant activity via inhibition of factor XIIa. Cardiovasc Hematol Agents Med Chem 21(2):108\u2013119","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"9","key":"3054_CR30","doi-asserted-by":"publisher","first-page":"10694","DOI":"10.1021\/acsomega.3c09335","volume":"9","author":"MD Woodland","year":"2024","unstructured":"Woodland MD, Thompson A, Lipford A, Goyal N, Schexnaildre JC, Mottamal M, Afosah DK, Al-Horani RA (2024) New Triazole-based potent inhibitors of human factor XIIa as anticoagulants. ACS Omega 9(9):10694\u201310708","journal-title":"ACS Omega"},{"issue":"3","key":"3054_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/1871525721666230126114224","volume":"21","author":"RA Al-Horani","year":"2023","unstructured":"Al-Horani RA (2023) 6-(Arylaminomethyl) isoquinolines as enzyme inhibitors and their Preparation: a patent highlight of factor XIIa inhibitors. Cardiovasc Hematol Agents Med Chem 21(3):243\u2013249","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"3054_CR32","doi-asserted-by":"publisher","first-page":"108831","DOI":"10.1016\/j.carres.2023.108831","volume":"529","author":"R Chiles","year":"2023","unstructured":"Chiles R, Afosah DK, Al-Horani RA (2023) Investigation of the anticoagulant activity of cyclic sulfated glycosaminoglycan mimetics. Carbohydr Res 529:108831","journal-title":"Carbohydr Res"},{"issue":"1","key":"3054_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/cbdd.14053","volume":"100","author":"RA Al-Horani","year":"2022","unstructured":"Al-Horani RA, Parsaeian E, Mohammad M, Mottamal M (2022) Sulfonated non-saccharide molecules and human factor XIa: enzyme inhibition and computational studies. Chem Biol Drug Des 100(1):64\u201379","journal-title":"Chem Biol Drug Des"},{"issue":"9","key":"3054_CR34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/ph14090886","volume":"14","author":"S Kar","year":"2021","unstructured":"Kar S, Bankston P, Afosah DK, Al-Horani RA (2021) Lignosulfonic Acid Sodium is a noncompetitive inhibitor of human factor XIa. Pharmaceuticals (Basel) 14(9):886","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"3054_CR35","doi-asserted-by":"publisher","first-page":"12699","DOI":"10.1021\/acsomega.1c00935","volume":"6","author":"RA Al-Horani","year":"2021","unstructured":"Al-Horani RA, Aliter KF, Kar S, Mottamal M (2021) Sulfonated Nonsaccharide Heparin mimetics are potent and noncompetitive inhibitors of human neutrophil elastase. ACS Omega 6(19):12699\u201312710","journal-title":"ACS Omega"},{"issue":"11","key":"3054_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/open.202000277","volume":"9","author":"S Kar","year":"2020","unstructured":"Kar S, Mottamal M, Al-Horani RA (2020) Discovery of Benzyl Tetraphosphonate derivative as inhibitor of human factor Xia. ChemistryOpen 9(11):1161\u20131172","journal-title":"ChemistryOpen"},{"issue":"3","key":"3054_CR37","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","volume":"65","author":"AK Dilger","year":"2022","unstructured":"Dilger AK, Pabbisetty KB, Corte JR, De Lucca I, Fang T, Yang W, Pinto DJP, Wang Y, Zhu Y, Mathur A, Li J, Hou X, Smith D, Sun D, Zhang H, Krishnananthan S, Wu DR, Myers JE Jr, Sheriff S, Rossi KA, Chacko S, Zheng JJ, Galella MA, Ziemba T, Dierks EA, Bozarth JM, Wu Y, Crain E, Wong PC, Luettgen JM, Wexler RR, Ewing WR (2022) Discovery of Milvexian, a High-Affinity, orally bioavailable inhibitor of factor XIa in Clinical studies for Antithrombotic Therapy. J Med Chem 65(3):1770\u20131785","journal-title":"J Med Chem"},{"issue":"2 Suppl","key":"3054_CR38","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S\u2013e43S","journal-title":"Chest"},{"issue":"2 Suppl","key":"3054_CR39","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e44S\u2013e88S","journal-title":"Chest"},{"issue":"2 Suppl","key":"3054_CR40","doi-asserted-by":"publisher","first-page":"e120S","DOI":"10.1378\/chest.11-2294","volume":"141","author":"JI Weitz","year":"2012","unstructured":"Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e120S\u2013e151S","journal-title":"Chest"},{"key":"3054_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/VHRM.S39726","volume":"11","author":"KP Cabral","year":"2015","unstructured":"Cabral KP, Ansell JE (2015) The role of factor xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag 11:117\u2013123","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"3054_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJMoa1601747","volume":"375","author":"AT Cohen","year":"2016","unstructured":"Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, APEX Investigators (2016) Extended thromboprophylaxis with Betrixaban in acutely Ill medical patients. N Engl J Med 375(6):534\u2013544","journal-title":"N Engl J Med"},{"issue":"7","key":"3054_CR43","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, RE-COVER II Trial Investigators (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772","journal-title":"Circulation"},{"issue":"9","key":"3054_CR44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"15","key":"3054_CR45","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"-VTE Hokusai","year":"2013","unstructured":"Hokusai -VTE, B\u00fcller I, D\u00e9cousus HR, Grosso H, Mercuri MA, Middeldorp M, Prins S, Raskob MH, Schellong GE, Schwocho SM, Segers L, Shi A, Verhamme M, Wells P P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415","journal-title":"N Engl J Med"},{"issue":"8","key":"3054_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ, RE-MEDY Trial Investigators; RE-SONATE Trial Investigators (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709\u2013718","journal-title":"N Engl J Med"},{"issue":"14","key":"3054_CR47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"EINSTEIN\u2013PE Investigators, B\u00fcller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"key":"3054_CR48","doi-asserted-by":"crossref","unstructured":"Bentounes NK, Melicine S, Martin AC, Smadja DM, Gendron N Development of new anticoagulant in 2023: prime time for anti-factor XI and XIa inhibitors. J Med Vasc 48(2):69\u201380","DOI":"10.1016\/j.jdmv.2023.04.002"},{"key":"3054_CR49","doi-asserted-by":"publisher","first-page":"1287487","DOI":"10.3389\/fphar.2023.1287487","volume":"14","author":"AC Clermont","year":"2023","unstructured":"Clermont AC, Murugesan N, Edwards HJ, Lee DK, Bayliss NP, Duckworth EJ, Pethen SJ, Hampton SL, Gailani D, Feener EP (2023) Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation. Front Pharmacol 14:1287487","journal-title":"Front Pharmacol"},{"issue":"1","key":"3054_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jth.15126","volume":"19","author":"JC Fredenburgh","year":"2021","unstructured":"Fredenburgh JC, Weitz JI (2021) New anticoagulants: moving beyond the direct oral anticoagulants. J Thromb Haemost 19(1):20\u201329","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3054_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","volume":"39","author":"JI Weitz","year":"2019","unstructured":"Weitz JI, Chan NC (2019) Advances in antithrombotic therapy. Arterioscler Thromb Vasc Biol 39(1):7\u201312","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"3054_CR52","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1161\/CIRCULATIONAHA.109.924761","volume":"121","author":"I Hagedorn","year":"2010","unstructured":"Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, Dickneite G, Nieswandt B (2010) Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121(13):1510\u20131517","journal-title":"Circulation"},{"issue":"19","key":"3054_CR53","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","volume":"118","author":"AS Revenko","year":"2011","unstructured":"Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, Gailani D, Monia BP, MacLeod AR (2011) Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 118(19):5302\u20135311","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03054-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03054-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T18:03:45Z","timestamp":1734113025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03054-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3054"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03054-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}